BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics, Inc. on 2025-12-19, according to the Form 8-K Amicus Therapeutics, Inc. filed with the SEC on 2026-04-27. The filing's Item 2.01 states no aggregate dollar price. Amicus Therapeutics, Inc. filed the report because the deal made it part of BioMarin Pharmaceutical Inc..
| Acquirer | BioMarin Pharmaceutical Inc. |
|---|---|
| Acquired | Amicus Therapeutics, Inc. |
| Completed | 2025-12-19 |
| Reported by | Amicus Therapeutics, Inc. (FOLD), the company acquired |
| Filing | Form 8-K, filed 2026-04-27 |
Want the whole picture on BioMarin Pharmaceutical Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioMarin Pharmaceutical Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioMarin Pharmaceutical Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the " SEC ") on December 19, 2025, Amicus Therapeutics, Inc., a Delaware corporation (the " Company "), entered into an Agreement and Plan of Merger (the " Merger Agreement "), dated December 19, 2025, with BioMarin Pharmaceutical Inc., a Delaware corporation (" Parent "), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Parent (" Merger Sub "), providing for the merger of Merger Sub with and into the Company (the " Merger "), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
More from the filing
Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.
On April 27, 2026, Merger Sub completed the Merger and merged with and into the Company, pursuant to the terms of the Merger Agreement.
The Company was the surviving corporation in the Merger (the " Surviving Corporation ") and, as a result, is now a wholly owned subsidiary of Parent.
Quoted from Amicus Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition BioMarin Pharmaceutical Inc. reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on BioMarin Pharmaceutical Inc.Look up BioMarin Pharmaceutical Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.